Monday, 05. August 2019, Newark, eCTD Submissions of IND and NDA/BLA to the US FDA, EU and Canada : 2-Day In-Person Seminar by Ex-FDA Official

from 05. August 2019 - 8:30
till 06. August 2019 - 16:30

Newark

Show map
0 people attending
Event description
The international agreement to assemble all Quality, Safety and Efficacy information for a drug or biologic product into a common format (called the CTD - Common Technical Document) has improved the speed and efficiency for companies working in global development programs and clarified expectations by regulatory bodies. Reformatting for multiple submissions is substantially limited. The CTD has improved the regulatory review processes and enabled implementation of good review practices. The eCTD has increased efficiency for reviewers and improved submission times.
This two day workshop will provide you with an in-depth review of the content and format requirements of the CTD/eCTD. Hands-on activities will include organizing specific study reports and other documents into the CTD, using tools for the project management of the CTD preparation, and pre-publishing an eCTD.
 
Who will Benefit:

Regulatory Affairs
Quality Assurance
Pharmacovigilance
Project Management
Regulatory Operations
Medical and Technical writers
Professionals preparing IND, DMFs, NDAs and other submissions
IT Professionals
Anyone responsible for providing content for the CTD


Show more
 Speaker:




Peggy J. BerryMBA, RAC,President & CEO, Synergy Consulting (Ex-FDA Official)

Peggy J. Berry, MBA, RAC, is the President & CEO at Synergy Consulting where she provides consulting services to companies in all aspects of drug development. She also provides group and one-on-one training in drug development, regulatory affairs and project management topics. Prior to founding Synergy Consulting in 2015, she was Vice President of Regulatory Affairs at Insmed (2/2015-5/2015) where she was responsible for the development and implementation of global regulatory strategies and the management and oversight of the regulatory affairs department. Prior to Insmed, she was Vice President of Regulatory Affairs and Quality at Amarin (3/2009-2/2014). She has also held a variety of senior level positions at Dyax (5/2006-3/2009), MGI Pharma (now Eisai; 7/2005-5/2006), AstraZeneca (10/2001-7/2005), and Dey Pharma (now Mylan; 12/1997-10/2001). She has also held Regulatory Affairs roles within two clinical contract research organizations (ILEX Oncology and Cato Research Ltd; 1992-1997) and has worked in review divisions at the FDA (1985-1992). In addition, Ms. Berry consults for a number of companies in the regulatory and quality area, conducts a number of training courses, and is active in the Regulatory Affairs Professionals Society. She is the editor of the 2010 book "Choosing the Right Regulatory Career" (RAPS, MD) and author of the 2011 book "Communication & Negotiation" (RAPS, MD).


For Registration - 
 
Note: Use coupon code REFERRAL10 and get 10% off on registration.

eCTD Submissions of IND and NDA/BLA to the US FDA, EU and Canada : 2-Day In-Person Seminar by Ex-FDA Official, Newark event

Find more interesting events
Get event recommendations based on your Facebook taste. Get it now!Show me the suitable events for meNot now